The final results of the PROVE3 study will be presented at this year’s annual meeting of the American Association for the Study of Liver Diseases. This phase 2 study was of telaprevir compared to a combination therapy of peginterferon alfa-2a and ribavirin. It intended to measure the 6 month and also 1-year durability of sustained viral response in genotype 1 patients with HCV who failed prior treatment with pegylated interferon and ribavirin.
According to John McHutchison, MD, principal investigator for this study, “This was the first large scale study performed in nonresponders to our current standard of care, which evaluated retreating these patients with the addition of an HCV-specific protease inhibitor. Its importance is, therefore, the proof of principle that adding this potent direct anti-viral allowed us to cure approximately 50 percent of this patient population who have failed therapy and for which no other options currently exists.”
The study included 453 patients, and the SVR rates in all treatment groups who received the telaprevir-based therapy were significantly higher than those who received peginterferon alfa-2a and ribavirin. All patients who received telaprevir and achieved virologic response maintained it for 48 weeks after the end of the treatment.
PROVE3 final results and 1-year durability of SVR with Telaprevir-based regimen in hepatitis C genotype 1-infected patients with prior nonresponse, viral breakthrough or relapse to Peginterferon-alfa-2a/b and Ribavirin therapy
